Comunicati Stampa
Salute e Benessere

The Galien Foundation Announces New Prix Galien UK Award Category for "Best Health Equity Innovation"

The Galien Foundation has been pleased to work with Trinity Life Sciences who have applied their health equity and life sciences expertise to shaping this new category. By introducing this category, the Prix Galien UK Committee aims to encourage both the life science industry and public institutions to pursue ground-breaking work that can lead to an improvement in equitable access to the health innovations that countless scientists deliver. The Galien Foundation has been pleased to work with...
LONDON, (informazione.news - comunicati stampa - salute e benessere)

The Galien Foundation has been pleased to work with Trinity Life Sciences who have applied their health equity and life sciences expertise to shaping this new category. By introducing this category, the Prix Galien UK Committee aims to encourage both the life science industry and public institutions to pursue ground-breaking work that can lead to an improvement in equitable access to the health innovations that countless scientists deliver.

"Recognizing equitable access to healthcare is crucial, as it remains a pressing challenge that continues to affect countless individuals," said Professor Sir Munir Pirmohamed , David Weatherall Chair of Medicine at the University of Liverpool and the NHS Chair of Pharmacogenetics. "The Galien Foundation is committed to celebrating breakthroughs that deepen our understanding of healthcare disparities and honoring those who are working to address unmet patient needs."

Bruno Cohen , Chairman of The Galien Foundation, added, "The Galien Foundation is excited to introduce this new category and partner with a leading global life sciences commercialization firm, Trinity Life Sciences, to recognize health equity leaders. This aligns with our mission to address access to innovation, bridging scientific breakthroughs with equitable healthcare to ensure life-saving innovations reach all in need."

"Trinity Life Sciences is honored to collaborate with The Galien Foundation in establishing this distinguished award category dedicated to advancing health equity," said Leslie Orne , President and Chief Executive Officer of Trinity Life Sciences. "This initiative recognizes organizations that demonstrate a commitment to improving equitable access to scientific innovation—whether through targeted investments in drug development and technology, research and development in underserved therapeutic areas, or policy initiatives that drive systemic change. Together, we are championing initiatives that inspire and accelerate progress toward a more inclusive and accessible healthcare landscape."

The contribution may fall within any of the following three broad categories:

Judges will evaluate submissions using these five criteria alongside a candidate's entry together with supporting documents:

To learn more about the new category and nominate an outstanding Health Equity Innovation, please visit: https://www.galienfoundation.org/prix-galien-uk

David Weatherall Chair of Medicine, University of Liverpool

Honorary Professor, University of Exeter , Consultant Radiologist, St George's Hospital London and former Chair Technology appraisal committee, NICE

Past Chair NICE Interventional Procedures and Medical Technologies Advisory Committees; Honorary Vascular Consultant and Professor, Exeter

Professor of Stroke Medicine at School of Cardiovascular and Metabolic Health in the College of Medical, Veterinary and Life Sciences at the University of Glasgow ; Consultant Physician in the Queen Elizabeth University Hospital, Glasgow

Chief Knowledge Officer - Conceivable Life Sciences, Senior Consultant – Hardian Health, Board Trustee – The Kings Fund, Honorary Senior Research Fellow, UCL

Vice President (Health), University of Warwick and President of Association of Innovation, Research and Technology Organisations, UK (AIRTO)

Director, Health Data Research UK, President of the Academy of Medical Sciences & Professor of Medicine and Vice Principal Data Science, University of Edinburgh

Master of Churchill College Cambridge

Chief Executive, Medicines and Healthcare products Regulatory Agency

Professor of Clinical Therapeutics, University of Oxford

Professor of Health Economics, Diagnosis and Screening

Professor of Clinical Pharmacology & Therapeutics, University of Liverpool

Sir John Crofton Professor of Respiratory Medicine, University of Edinburgh

With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. We serve over 300 pharmaceutical, biotech and medical device clients, helping them develop the right drugs and devices for today's market and optimize them once in market. We have a diverse staff of over 1200 people and 11 global offices across the U.S., Europe and Asia . Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit TrinityLifeSciences.com.

The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.

The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter being established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information, visit  www.galienfoundation.org .

Follow the Foundation on social media: 
https://www.facebook.com/GalienFoundation/ 
https://twitter.com/GalienFdn
https://www.linkedin.com/company/the-galien-foundation/

Julian Tyndale-Biscoe
Finn Partners
Julian.Tyndale-biscoe@finnpartners.com
+44 20 3217 7060

Kara Bradley
Finn Partners
Kara.Bradley@finnpartners.com
646-213-7243

Logo - https://mma.prnewswire.com/media/564722/The_Galien_Foundation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-galien-foundation-announces-new-prix-galien-uk-award-category-for-best-health-equity-innovation-302377646.html

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili